Company: MBIO
Filing Date: 2025-01-22
Form Type: DEF 14C
Source: 0001104659-25-005251
Chunk: 12

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-22
Form: DEF 14C
Chunk 12
---
 practice of “householding” information statements. This means that only
one copy of this Information Statement may have been sent to multiple stockholders in your household. We will promptly deliver a separate
copy of the Information Statement to you if you contact us at: Mustang Bio, Inc., 377 Plantation Street, Worcester, Massachusetts 01605,
Attn: Corporate Secretary. You may also contact us at (781) 652-4500.

If you want to receive separate
copies of Information Statements in the future, or if you are receiving multiple copies and would like to receive only one copy for your
household, you should contact your bank, broker, or other nominee record holder, or you may contact us at the above address or phone
number.

<div align='center'>MISCELLANEOUS MATTERS</div>

The entire cost of furnishing
this Information Statement will be borne by the Company. We will request brokerage houses, nominees, custodians, fiduciaries and other
like parties to forward this Information Statement to the beneficial owners of the common stock held of record by them and will reimburse
such persons for their reasonable charges and expenses in connection therewith. The Board has fixed the close of business on January
14, 2025 as the Record Date for the determination of stockholders who are entitled to receive this Information Statement.

This Information Statement is being mailed on
or about January 22,
2025 to all stockholders of record as of the Record Date.

<div align='center'>CONCLUSION</div>

As a matter of regulatory
compliance, we are sending you this Information Statement that describes the purpose and effect of the above actions. Your consent to
the above action is not required and is not being solicited in connection with this action. This Information Statement is intended to
provide our stockholders information required by the rules and regulations of the Exchange Act.

| BY ORDER OF THE BOARD OF DIRECTORS 
 January 22,                        
 2025                               | By: | /s/ Manuel Litchman, M.D.                                              |
|:-----------------------------------|:----|:-----------------------------------------------------------------------|
|                                    |     | Manuel Litchman, M.D.                                                  |
|                                    |     | President, Chief Executive Officer and Interim Chief Financial Officer |